Latest by Barbara Jungwirth

This Week in HIV Research: HIV Antiretrovirals vs. HPV

The effect of HIV treatment on HPV risk; bone mineral density declines in women vs. men; how hep C cure affects kidney function; when it comes to non-daily PrEP, location matters.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: The Perils of Polypharmacy

The risks of multiple non-HIV medication prescriptions; PrEP use and sexually transmitted infection incidence; how vaginal bacteria relate to HIV seroconversion; the effect of early treatment on HIV in the brain.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: When Prioritizing Treatment, Look Beyond CD4

Gauging treatment priority when CD4 count is high; the effect of hepatitis C coinfection on response to HIV treatment; HIV, aging and comorbidity in Africa; PrEP and drug-resistant gonorrhea.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: This Is Your Brain on (HIV) Drugs

NeuroAIDS while on efavirenz vs. common NRTIs; HIV and the smoking cessation aid varenicline; PrEP adherence after positive partners start treatment; and Ugandans underreporting their antiretroviral use.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Where's the PrEP?

This week: PrEP remains deeply underprescribed in North Carolina; and recent studies explore the effects of inflammation, age, and serum albumin on serious non-AIDS event risk.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: To Seek and to Treat

This week: the successes of Vancouver's harm reduction and HIV outreach programs; the safety of stem-cell transplantation; how biomarkers predict health events; and how to improve partner notification.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: A Viral Prediction

Our latest jaunt through HIV journals looks at a symptom-based scoring system to predict acute HIV, the effect of a person's sex on psychomotor function, and the value of vitamin D supplementation to moderate lipid levels.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: You Don't Know Jak

Among the research covered this week are fresh findings regarding Jak inhibitors, an exciting experimental class of HIV medications.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Looking Forward, Looking Back

In our final installment of 2017, we intermingle forward-looking research with some retrospective analysis. We begin our four-study tour by joining researchers in Tennessee for an exercise in HIV outbreak prediction.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: The Duracell Batteries of Antiretroviral Therapy

Among this week's selection of four studies, we learn about data from a large study exploring the relative durability of first-line antiretroviral regimens stratified by drug class. (Spoiler alert: Older protease inhibitors don't do so well.)

By Barbara Jungwirth and Myles Helfand